Johnson & Johnson Stock
€143.48
Your prediction
Johnson & Johnson Stock
Johnson Johnson is a multinational company that focuses on the development, manufacturing, and marketing of a wide range of consumer health products, medical devices, and pharmaceuticals. The company was founded in 1886 and is headquartered in New Jersey, USA. It operates in more than 60 countries and has a diverse portfolio of popular brands including Band-Aid, Tylenol, and Neutrogena. As of 2021, Johnson Johnson has a market capitalization of over $435 billion and is listed on the New York Stock Exchange under the symbol JNJ.
Pros and Cons of Johnson & Johnson in the next few years
Pros
Cons
Performance of Johnson & Johnson vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Johnson & Johnson | 0.060% | 1.948% | 10.155% | -3.082% | 3.106% | -16.160% | 14.354% |
| Pfizer Inc. | 0.520% | 1.011% | 1.525% | -26.001% | -17.324% | -57.831% | -33.809% |
| Elanco Animal Health Inc. | 0.310% | 0.223% | 3.049% | 6.487% | 8.885% | -37.691% | -30.214% |
| Biogen Inc. | -0.130% | 6.289% | 3.575% | -42.633% | -22.562% | -46.957% | -53.424% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Johnson & Johnson, symbolized as JNJ, holds a prominent position in the Pharmaceutical industry. Reviewing their financial data indicate robust financial base and promising trends over the years. Their capacity to generate revenues and maintain substantial margins underscores their operational efficiency. On the flip side, the high levels of liabilities and debts might raise some eyebrows. The analysis below explores these aspects in depth.
Reflecting upon the income statement for the years 2020, 2021 and 2022, it's clear that JNJ has shown consistent growth in net income. For instance, in 2022, the net income was listed at $17.94 billion compared to $14.71 billion in 2020. Not just the net income, even the gross profit has shown positive trends, increasing from $54.15 billion in 2020 to $63.85 billion in 2022, reinforcing their capacity to improve operational efficiency and drive profits.
The cash flow statements for the corresponding years paint a similar picture. The total cash from operating activities for 2022 was $21.19 billion as compared to $23.53 billion in 2020. While there was a slight drop, the numbers clearly indicate that Johnson & Johnson has maintained substantial cash flow from its main line of business.
Comments
News
Johnson & Johnson Stock: Cancer Breakthroughs Spark Mixed Market Reactions
Johnson & Johnson is generating significant attention in both medical and financial circles following impressive study results for its multiple myelom treatments. The pharmaceutical giant's cancer
Johnson & Johnson Stock: Acquisition Progress Amid Talc Setback
Johnson & Johnson is advancing toward completing its strategic acquisition of Intra-Cellular Therapies, expected to finalize around April 2, 2025, following shareholder approval on March 27. The
Johnson & Johnson Stock: Court Setback Triggers Financial Shift
Johnson & Johnson (J&J) faces a significant legal defeat as a US bankruptcy court in Texas rejected its subsidiary Red River Talc LLC's proposed settlement plan. This plan, valued at approximately